Vaxcyte, Inc

Market analysts have deemed the US Food and Drug Administration’s COVID-19 vaccine policy unveiled 20 May as far from a worst-case scenario for vaccine-focused firms – for example, approved vaccines w

While President Trump’s efforts to downsize the US Food and Drug Administration and plans to impose tariffs are currently spooking biopharma investors, some companies were able to defy the gloomy sent

News that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for